Biocon facility in Malaysia found to have issues once again by the FDA
15 Aug 2023
A recent FDA inspection of a Biocon manufacturing facility in Malaysia has revealed more issues relating to cleanliness.
The regulator inspected Biocon’s manufacturing facility in Iskandar Puteri, located near Singapore, between July 10 and July 20. The site manufactures sterile drugs, including insulin glargine, a biosimilar version of Sanofi’s Lantus.
The 10-page report cites cleaning deficiencies for tools and problems related to airflow in aseptic areas. It also reported a lack of integrity testing, which is done to ensure there are no defects, such as tears or pinholes, before the manufacturing of sterile drug products.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.